Compare BIO & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BIO | IBRX |
|---|---|---|
| Founded | 1952 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.1B | 8.2B |
| IPO Year | 1994 | 2015 |
| Metric | BIO | IBRX |
|---|---|---|
| Price | $364.61 | $10.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $328.33 | $12.75 |
| AVG Volume (30 Days) | 256.4K | ★ 11.3M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 142.61 | 38.71 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,583,200,000.00 | $113,288,000.00 |
| Revenue This Year | N/A | $99.26 |
| Revenue Next Year | $2.13 | $101.32 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.65 | ★ 668.31 |
| 52 Week Low | $236.73 | $1.95 |
| 52 Week High | $396.23 | $12.43 |
| Indicator | BIO | IBRX |
|---|---|---|
| Relative Strength Index (RSI) | 45.64 | 62.49 |
| Support Level | $358.85 | $6.68 |
| Resistance Level | $392.81 | $10.82 |
| Average True Range (ATR) | 12.52 | 0.59 |
| MACD | -2.22 | 0.13 |
| Stochastic Oscillator | 30.27 | 70.90 |
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.